BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer

NCT00326495 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

NIH

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Cetuximab
DRUG: BAY 43-9006

Sponsor

National Cancer Institute (NCI)